INDRAMEDCO

Indraprastha Medical Corporation Limited announced on May 27, 2026, that ICRA Limited has reaffirmed its long-term credit rating for bank facilities and instruments at [ICRA]AA(Stable) and short-term rating at [ICRA]A1+ as of May 26, 2026. This includes a total of ₹162.50 crore across term loans, cash credit, and non-fund-based facilities, indicating a stable financial outlook.

For the year ended 31st March, 2026, Revenue from operations was ₹1,482.51 Cr vs ₹1,356.36 Cr (▲9.30% YoY), EBITDA was ₹266.92 Cr vs ₹244.27 Cr (▲9.27% YoY), and PAT was ₹183.62 Cr vs ₹160.99 Cr (▲14.06% YoY). EBITDA Margin was 18.00% vs 18.01% (▼1bps). The Board recommended a dividend of ₹4.00 per equity share for FY 2025-26, subject to shareholder approval.

Indraprastha Medical Corporation Limited's Board of Directors, in a meeting on May 12, 2026, approved the Audited Financial Statements and Results for the quarter and year ended March 31, 2026. The Board also recommended a dividend of 40%, equating to Rs. 4.00 per equity share, for the financial year 2025-26, subject to shareholder approval at the upcoming AGM. The auditors provided an unmodified opinion on the financial results.

Indraprastha Medical Corporation Limited filed a Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March 2026. The certificate, issued by MUFG Intime India Private Limited, confirms timely processing of dematerialisation requests.

Mr. Vinayak Chatterjee completed his second term as an Independent Director on the Board of Directors on March 31, 2026, and consequently ceased to be a Director and Committee Member/Chairperson.

The trading window will close from April 1, 2026, until 48 hours after the announcement of audited financial results for the quarter and year ending March 31, 2026, as per SEBI (Prohibition of Insider Trading) Regulations, 2015.

Indraprastha Medical Corporation Limited's postal ballot results, with e-voting concluded on March 20, 2026, show that all resolutions were duly passed. This includes the re-appointment of three existing Independent Directors and the appointment of a new Independent Director.

Indraprastha Medical Corporation Limited issued a Postal Ballot Notice seeking shareholder approval for the re-appointment of Mr. Salil Singhal, Ms. Vineeta Rai, and Ms. Madhumita Ganguli as Independent Directors, and the appointment of Mr. Harsh Pati Singhania as an Independent Director. E-voting will be held from February 19, 2026, to March 20, 2026.

Company's Revenue from operations stood at ₹371.61 Cr vs ₹324.93 Cr (▲14.4% YoY), EBITDA ₹61.95 Cr vs ₹52.19 Cr (▲18.7% YoY), and PAT ₹41.00 Cr vs ₹32.81 Cr (▲25.0% YoY). EBITDA Margin expanded to 16.67% from 16.06% (▲61bps). The Board also approved the appointment of one new Independent Director and re-appointment of three existing Independent Directors. Additionally, the company noted an affidavit filed by the Govt. of NCT of Delhi regarding a pending Supreme Court case on the Free Patient Matter related to the hospital's land lease.

New Filing detected. See link for details.

Revenue from operations ₹371.61Cr vs ₹324.93Cr (▲14.4% YoY), EBITDA ₹61.95Cr vs ₹52.19Cr (▲18.7% YoY), PAT ₹41.00Cr vs ₹32.81Cr (▲25.0% YoY). EBITDA Margin 16.7% vs 16.1% (▲60bps). The company also noted an additional affidavit filed by the Govt. of NCT of Delhi in a pending Supreme Court case regarding the hospital's land lease.

Consolidated Revenue ₹371.61Cr vs ₹324.93Cr (▲14.4% YoY), EBITDA ₹61.95Cr vs ₹52.19Cr (▲18.7% YoY), PAT ₹41.00Cr vs ₹32.81Cr (▲25.0% YoY). EBITDA Margin 16.67% vs 16.06% (▲61bps).

Revenue from operations ₹371.61Cr vs ₹324.93Cr (▲14.4% YoY), EBITDA ₹61.95Cr vs ₹52.19Cr (▲18.7% YoY), PAT ₹41.00Cr vs ₹32.81Cr (▲25.0% YoY). EBITDA Margin 16.67% vs 16.06% (▲61bps). The Board also approved the re-appointment of four Independent Directors and noted an affidavit filed by the Govt. of NCT of Delhi regarding a pending Free Patient Matter in the Supreme Court.

Standalone Revenue ₹371.61Cr vs ₹324.93Cr (▲14.36% YoY), EBITDA ₹61.95Cr vs ₹52.19Cr (▲18.70% YoY), PAT ₹41.00Cr vs ₹32.81Cr (▲24.95% YoY). EBITDA Margin 16.67% vs 16.06% (▲61bps). The Board also approved the appointment of Mr. Harsh Pati Singhania and re-appointment of Mr. Salil Singhal, Ms. Vineeta Rai, and Ms. Madhumita Ganguli as Independent Directors.